Chris Verslype

1999–2025 年に発表

110
論文数
23,213
被引用数
66
h 指数
103
i10 指数

被引用数

Chris Verslype の年別被引用数1991 年: 被引用 1 件1996 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 5 件2004 年: 被引用 31 件2005 年: 被引用 100 件2006 年: 被引用 118 件2007 年: 被引用 137 件2008 年: 被引用 157 件2009 年: 被引用 160 件2010 年: 被引用 178 件2011 年: 被引用 149 件2012 年: 被引用 177 件2013 年: 被引用 172 件2014 年: 被引用 157 件2015 年: 被引用 150 件2016 年: 被引用 139 件2017 年: 被引用 132 件2018 年: 被引用 121 件2019 年: 被引用 637 件2020 年: 被引用 824 件2021 年: 被引用 915 件2022 年: 被引用 729 件2023 年: 被引用 620 件2024 年: 被引用 981 件2025 年: 被引用 455 件2026 年: 被引用 8 件1992〜1995 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,171 件、この内訳の 19.7%中国: 引用元論文 1,773 件、この内訳の 16.1%イタリア: 引用元論文 771 件、この内訳の 7%ドイツ: 引用元論文 651 件、この内訳の 5.9%イギリス: 引用元論文 565 件、この内訳の 5.1%フランス: 引用元論文 505 件、この内訳の 4.6%スペイン: 引用元論文 446 件、この内訳の 4%日本: 引用元論文 434 件、この内訳の 3.9%韓国: 引用元論文 303 件、この内訳の 2.8%ベルギー: 引用元論文 287 件、この内訳の 2.6%オランダ: 引用元論文 275 件、この内訳の 2.5%カナダ: 引用元論文 263 件、この内訳の 2.4%
0%19.7%その他 23.4%

分野

  • Medicine76.9%
  • Biochemistry, Genetics and Molecular Biology16.3%
  • Immunology and Microbiology3%
  • Engineering0.7%
  • Nursing0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他2%

トピック

  • Hepatocellular Carcinoma Treatment and Prognosis10.9%
  • Cancer Immunotherapy and Biomarkers5%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4.9%
  • Colorectal Cancer Treatments and Studies4.2%
  • Liver Disease Diagnosis and Treatment3.5%
  • Pancreatic and Hepatic Oncology Research3.5%
  • その他68%

共著者

全論文

検索で開く
  1. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita - The Lancet Oncology 2018 被引用: 2,536

  2. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn ほか 116 名 - The Lancet 2023 被引用: 1,025

  3. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2018 被引用: 1,070

  4. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Naohiro Gotoh, Kwok‐Kin Wong, Catherine M. Verfaillie, Rita Derua, Sebastian Munck, Mariia Yuneva, Laura Beretta, Ralph J. DeBerardinis, Johannes V. Swinnen, Leanne Hodson, David Cassiman, Chris Verslype, Sven Christian, Sylvia Grünewald, Thomas G. P. Grünewald, Sarah‐Maria Fendt - Nature 2019 被引用: 484

  5. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , - New England Journal of Medicine 2004 被引用: 5,049

  6. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 458

  7. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Van Cutsem - ESMO Open 2023 被引用: 161

  8. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2018 被引用: 335

  9. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard S. Finn, Swan N. Thung, Augusto Villanueva, Daniela Sia, Josep M. Llovet - Gastroenterology 2022 被引用: 146

  10. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

    著者: , , , , , , , , , , , , , , , - Journal of Hepatology 2019 被引用: 396

  11. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2022 被引用: 129

  12. PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma

    著者: , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 82

  13. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 被引用: 84

  14. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas

    著者: , , , , , , , , , , , , , , , , , , , , - Gut 2013 被引用: 271

  15. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , René Adam, René Adam, Céline Piedvache, Laurence Chiche, Jean Philippe Adam, Ephrem Salamé, Petru Bucur, Daniel Cherqui, Olivier Scatton, Victoire Granger, Michel Ducreux, Umberto Cillo, François Cauchy, Jean-Yves Mabrut, François Cauchy, Jean-Yves Mabrut, Chris Verslype, Laurent Coubeau, Jean Hardwigsen, Emmanuel Boleslawski, Fabrice Muscari, Heithem Jeddou, Denis Pezet, Bruno Heyd, Valerio Lucidi, Karen Geboes, Jan Lerut, Pietro Majno, Lamiae Grimaldi, Francis Levi, Maïté Lewin, Maximiliano Gelli, Olivier Soubrane, Mickael Lesurtel, Jean Baptsite Bachet, Samuel Lesourd, Marine Jary, Mohamed Bouattour, Sara Lonardi, Mohamed Hebbar, Karim Boudjema, Denis Smith, Mircea Chirica, Thierry Lecomte, Chirstophe Borg, Rosine Guimbaud, Julien Taieb, Patrizia Burra, Philippe Rougier, Joan Figueras - The Lancet 2024 被引用: 159

  16. Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 276

  17. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 643

  18. 18F-AlF-NOTA-Octreotide Outperforms68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study

    著者: , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2022 被引用: 70

  19. Transition from laparoscopic to robotic liver surgery: clinical outcomes, learning curve effect, and cost-effectiveness

    著者: , , , , , , , , - Journal of Robotic Surgery 2022 被引用: 37

  20. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes

    著者: , , , , , , , , , , , , - Hepatology 2012 被引用: 330

  21. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory Kaltsas, Branislav Klimàcek, Ulrich Knigge, Agnieszka Kolasińska-Ćwikła, Walter Kolb, Beata Kos‐Kudła, Catarina Alisa Kunze, Stefania Landolfi, Stefano La Rosa, Carlos López, Kerstin Lorenz, Maurice Matter, Peter Mazal, Claudia Mestre‐Alagarda, Patricia Morales del Burgo, Els J.�M. Nieveen van Dijkum, Kira Oleinikov, Lorenzo A. Orci, Francesco Panzuto, Marianne Pavel, Marine Perrier, Henrik M. Reims, Guido Rindi, Anja Rinke, Maria Rinzivillo, Xavier Sagaert, I. Satiroglu, Andreas Selberherr, Alexander Siebenhüner, Margot Tesselaar, M. Thalhammer, Espen Thiis‐Evensen, Christos Toumpanakis, Timon Vandamme, José G. van den Berg, Alessandro Vanoli, Marie‐Louise F. van Velthuysen, Chris Verslype, Stephan A. Vorburger, Alessandro Lugli, John Ramage, Marcel Zwahlen, Aurel Perren, Reto M. Kaderli - The Lancet Oncology 2023 被引用: 66

  22. Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 34

  23. 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

    著者: , , , , , , , - Journal of Nuclear Medicine 2023 被引用: 33

  24. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2004 被引用: 774